MacroGenics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MGNX Nasdaq 2830 www.macrogenics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences - Nov 5th, 2026 2:05 pm
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors - Nov 3rd, 2026 2:05 pm
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates - Oct 29th, 2026 2:35 pm
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer - Oct 26th, 2026 5:06 am
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN - Oct 23rd, 2026 7:15 am
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors - Oct 15th, 2026 2:05 pm
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Oct 9th, 2026 6:40 am
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Sep 23rd, 2026 7:40 am
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 9th, 2026 2:05 pm
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Aug 14th, 2026 6:50 pm
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Aug 13th, 2026 4:50 pm
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - Aug 13th, 2026 2:05 pm
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - Aug 11th, 2026 2:05 pm
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates - Aug 6th, 2026 3:40 pm
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 - Jul 23rd, 2026 2:01 pm
R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy - Jul 5th, 2026 4:52 pm
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Jul 2nd, 2026 4:40 pm
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? - Jul 2nd, 2026 10:00 am